OptiNose (OPTN) News Today $6.38 +0.35 (+5.80%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCEJanuary 18 at 12:27 AM | msn.comOptinose, Inc.: Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionJanuary 16, 2025 | finanznachrichten.deOptinose price target adjusted for stock split at Lake StreetJanuary 16, 2025 | markets.businessinsider.comLake Street Capital Has Lowered Expectations for OptiNose (NASDAQ:OPTN) Stock PriceLake Street Capital cut their target price on OptiNose from $45.00 to $17.00 and set a "buy" rating on the stock in a research report on Thursday.January 16, 2025 | marketbeat.comLake Street Remains a Buy on Optinose (OPTN)January 16, 2025 | markets.businessinsider.comOptinose Reports Q4 XHANCE Net Product Revenue; Sees Continued Growth In Year AheadJanuary 15, 2025 | markets.businessinsider.comOptinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionJanuary 15, 2025 | globenewswire.comHC Wainwright Forecasts OptiNose FY2029 EarningsOptiNose, Inc. (NASDAQ:OPTN - Free Report) - Research analysts at HC Wainwright issued their FY2029 EPS estimates for OptiNose in a note issued to investors on Friday, January 3rd. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of $1.41 per share for the year. HCJanuary 6, 2025 | marketbeat.comOptinose price target adjusted for stock split at H.C. WainwrightJanuary 3, 2025 | msn.comHC Wainwright Issues Positive Forecast for OptiNose (NASDAQ:OPTN) Stock PriceHC Wainwright upped their price objective on OptiNose from $5.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday.January 3, 2025 | marketbeat.comOptiNose (NASDAQ:OPTN) Shares Down 6.1% - Time to Sell?OptiNose (NASDAQ:OPTN) Shares Down 6.1% - What's Next?January 2, 2025 | marketbeat.comOptiNose trading halted, volatility trading pauseJanuary 1, 2025 | markets.businessinsider.comOptiNose (NASDAQ:OPTN) Sees Unusually-High Trading Volume - Here's WhyOptiNose (NASDAQ:OPTN) Sees Unusually-High Trading Volume - Here's What HappenedDecember 31, 2024 | marketbeat.comOptiNose trading halted, news pendingDecember 31, 2024 | markets.businessinsider.comOptinose, Inc.: Optinose Announces 1-for-15 Reverse Stock SplitDecember 28, 2024 | finanznachrichten.deOptiNose, Inc. (NASDAQ:OPTN) Short Interest UpdateOptiNose, Inc. (NASDAQ:OPTN - Get Free Report) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totalling 3,190,000 shares, a decline of 56.7% from the November 30th total of 7,360,000 shares. Based on an average daily trading volume, of 754,800 shares, the short-interest ratio is currently 4.2 days.December 27, 2024 | marketbeat.comOptiNose Stock Scheduled to Reverse Split on Tuesday, December 31st (NASDAQ:OPTN)OptiNose, Inc. (NASDAQ:OPTN - Free Report) shares are scheduled to reverse split before the market opens on Tuesday, December 31st. The 1-15 reverse split was announced on Thursday, December 26th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 30th.December 27, 2024 | marketbeat.comOptinose Sets 1-for-15 Reverse Stock SplitDecember 26, 2024 | markets.businessinsider.comOptinose Announces 1-for-15 Reverse Stock SplitDecember 26, 2024 | globenewswire.comOptinose to Present at Piper Sandler Healthcare ConferenceDecember 4, 2024 | msn.comOptinose to Present at the Piper Sandler 36th Annual Healthcare ConferenceDecember 2, 2024 | globenewswire.comFormer Optinose CEO Peter Miller comes out of retirement to launch new startupDecember 2, 2024 | bizjournals.comOptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price TargetNovember 16, 2024 | finance.yahoo.comFY2024 EPS Estimates for OptiNose Raised by HC WainwrightOptiNose, Inc. (NASDAQ:OPTN - Free Report) - Investment analysts at HC Wainwright raised their FY2024 EPS estimates for shares of OptiNose in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will earn (November 15, 2024 | marketbeat.comOptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised GuidanceNovember 13, 2024 | finance.yahoo.comOptinose price target lowered to $1 from $3 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comOptinose (OPTN) Gets a Buy from Piper SandlerNovember 13, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for OptiNose (NASDAQ:OPTN)HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of OptiNose in a report on Wednesday.November 13, 2024 | marketbeat.comOptinose Shows Prescription Growth Amid Revenue ChallengesNovember 13, 2024 | markets.businessinsider.comOptinose, Inc.: Optinose Reports Third Quarter 2024 Financial Results and Recent Operational HighlightsNovember 12, 2024 | finanznachrichten.deOptinose reports Q3 EPS 0c, consensus (5c)November 12, 2024 | markets.businessinsider.comInsights Ahead: OptiNose's Quarterly EarningsNovember 12, 2024 | benzinga.comOptinose cuts FY24 XHANCE revenue view to $75M-$79M from $85M-$90MNovember 12, 2024 | markets.businessinsider.comOptiNose Inc (OPTN) Q3 2024 Earnings Report Preview: What To ExpectNovember 12, 2024 | finance.yahoo.comOptiNose, Inc. (OPTN) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comOptiNose, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 12, 2024 | seekingalpha.comOptinose Reports Third Quarter 2024 Financial Results and Recent Operational HighlightsNovember 12, 2024 | globenewswire.comOptinose to Announce Q3 2024 Financial Results with Investor CallNovember 8, 2024 | msn.comOptiNose (OPTN) Scheduled to Post Quarterly Earnings on TuesdayOptiNose (NASDAQ:OPTN) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comOptinose Announces Reporting Date for Third Quarter 2024 Financial ResultsNovember 5, 2024 | globenewswire.comPositive week for OptiNose, Inc. (NASDAQ:OPTN) institutional investors who lost 24% over the past yearOctober 20, 2024 | finance.yahoo.comRosalind Advisors, Inc. Expands Stake in OptiNose IncOctober 18, 2024 | finance.yahoo.comOptinose Grants Stock Options to Attract New TalentOctober 18, 2024 | msn.comOptinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 16, 2024 | globenewswire.comOptiNose Inc (OPTN) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ...October 10, 2024 | finance.yahoo.comLake Street Sticks to Their Buy Rating for Optinose (OPTN)October 9, 2024 | markets.businessinsider.comOptinose Appoints Terry Kohler As CFOOctober 8, 2024 | markets.businessinsider.comOptinose Appoints Terry Kohler as Chief Financial OfficerOctober 7, 2024 | globenewswire.com2,350,010 Shares in OptiNose, Inc. (NASDAQ:OPTN) Purchased by Stonepine Capital Management LLCStonepine Capital Management LLC bought a new stake in OptiNose, Inc. (NASDAQ:OPTN - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,350,010 shares of the company's stock, valued at approximately $2,444,000. OptiNoseOctober 1, 2024 | marketbeat.comGreat Point Partners LLC Increases Stock Position in OptiNose, Inc. (NASDAQ:OPTN)Great Point Partners LLC grew its position in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 56.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,727,097 shares of the company's stock after purchasing an additional 4,940,779 sSeptember 24, 2024 | marketbeat.com Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address OPTN Media Mentions By Week OPTN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPTN News Sentiment▼0.000.44▲Average Medical News Sentiment OPTN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPTN Articles This Week▼92▲OPTN Articles Average Week Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Heron Therapeutics News Amylyx Pharmaceuticals News Neurogene News Atai Life Sciences News DiaMedica Therapeutics News UroGen Pharma News Eledon Pharmaceuticals News Lifecore Biomedical News Foghorn Therapeutics News Benitec Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPTN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
